The pretreatment serum levels of VEGF may be an independent prognostic marker for inoperable NSCLC, and therefore may be identified as an indicator to predict the outcome of patients with inoperable NSCLC. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.